Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effect of 1,25-dihydroxyvitamin D3 on plasma prolactin in patients with renal failure on regular dialysis treatment.

Literature DB >> 6689332

Effect of 1,25-dihydroxyvitamin D3 on plasma prolactin in patients with renal failure on regular dialysis treatment.

D Verbeelen, L Vanhaelst, A C Van Steirteghem, J Sennesael.

Abstract

Basal plasma prolactin (PRL) has been measured in 6 patients with chronic renal failure 3 months before and at monthly intervals during a 3 months 1,25-dihydroxyvitamin D3 [1,25 (OH)2-D] treatment. Plasma PRL decreased rapidly during, 1,25 (OH)2-D treatment, while it remained unchanged during the 3-months control period. There was no correlation between PRL and parathyroid hormone (PTH; measured either with carboxy- or amino-terminal assays) and several other parameters. A direct effect of 1,25 (OH)2-D on PRL secretion may exist.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1983 PMID： 6689332 DOI： 10.1007/bf03347616

Source DB: PubMed Journal: J Endocrinol Invest ISSN： 0391-4097 Impact factor: 4.256

21 in total

1. Evidence for a 1,25-dihydroxyvitamin D3 receptor-like macromolecule in rat pituitary.

Authors: M R Haussler; S C Manolagas; L J Deftos
Journal: J Biol Chem Date: 1980-06-10 Impact factor: 5.157

2. The pituitary-testicular axis in men with chronic renal failure.

Authors: S Holdsworth; R C Atkins; D M de Kretser
Journal: N Engl J Med Date: 1977-06-02 Impact factor: 91.245

3. Role of calcium in the thyrotropin-releasing hormone-stimulated release of prolactin from pituitary cells in culture.

Authors: A H Tashjian; M E Lomedico; D Maina
Journal: Biochem Biophys Res Commun Date: 1978-04-14 Impact factor: 3.575

4. Abnormalities in the regulation of prolactin in patients with chronic renal failure.

Authors: G Ramirez; W M O'Neill; H A Bloomer; W Jubiz
Journal: J Clin Endocrinol Metab Date: 1977-10 Impact factor: 5.958

5. Regulation of pituitary function and prolactin production in the GH4 cell line by vitamin D.

Authors: G H Murdoch; M G Rosenfeld
Journal: J Biol Chem Date: 1981-04-25 Impact factor: 5.157

6. Renal osteodystrophy.

Authors: J W Coburn
Journal: Kidney Int Date: 1980-05 Impact factor: 10.612

7. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid.

Authors: W E Stumpf; M Sar; F A Reid; Y Tanaka; H F DeLuca
Journal: Science Date: 1979-12-07 Impact factor: 47.728

8. Prolactin and calcitonin responses to parathyroid hormone infusion in hypoparathyroid, pseudohypoparathyroid, and normal subjects.

Authors: A S Brickman; H E Carlson; L J Deftos
Journal: J Clin Endocrinol Metab Date: 1981-09 Impact factor: 5.958

Effect of 1,25-dihydroxyvitamin D3 on plasma prolactin in patients with renal failure on regular dialysis treatment.

1. Evidence for a 1,25-dihydroxyvitamin D3 receptor-like macromolecule in rat pituitary.

2. The pituitary-testicular axis in men with chronic renal failure.

3. Role of calcium in the thyrotropin-releasing hormone-stimulated release of prolactin from pituitary cells in culture.

4. Abnormalities in the regulation of prolactin in patients with chronic renal failure.

5. Regulation of pituitary function and prolactin production in the GH4 cell line by vitamin D.

6. Renal osteodystrophy.

7. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid.

8. Prolactin and calcitonin responses to parathyroid hormone infusion in hypoparathyroid, pseudohypoparathyroid, and normal subjects.

9. [The effect of an intravenous calcium load on plasma prolactin in man (author's transl)].

10. Hyperprolactinaemia in renal disease.

Review 1. Drug-induced changes in prolactin secretion. Clinical implications.

2. Effect of 1,25-dihydroxyvitamin D3 and nifedipine on prolactin release in normal man.